Gapping up
In reaction to strong earnings/guidance: LULU +5.3%, ARGS +2.9%, GOL+0.7%
Select metals/mining stocks trading higher: RIO +3.4%, BBL +3.3%, CLF+2.7%, FCX +1.6%, X +1.1%
Select oil/gas related names showing strength: STO +3.7%, CHK +3.5%, BP+3.4%, RDS.A +3.3%, PBR +2.1%, OAS +1.4%
Other news: ACAD +23.7% (affirms favorable AdComm review for NUPLAZID for the treatment of psychosis associated with Parkinson's disease) VICL +16.7% (announces that the FDA has granted fast track designation for its investigational antifungal product candidate, VL-2397, for the treatment of invasive aspergillosis), ATNM +8.9% (granted orphan designation by the FDA for its 131I-BC8 monoclonal antibody for the treatment of Acute Myeloid Leukemia), GLMD +7.5% (pre-clinical data demonstrating significant anti-fibrotic activity of AramcholTM in methionine and choline deficient diet in mice), ADAP +5.1% (confirms orphan drug designation to Adaptimmune's T-cell therapy targeting NY-ESO for treatment of soft tissue sarcoma), VRX +3.9% (launches process to obtain an amendment and waiver to its credit facility, intends to file 10-K on or before April 29), LODE +2.3% (prices offering of 10 mln shares of common stock at $0.35/share), TSLA +1.5% (still checking, likely higher with Futures), BABA +1.4% (trading higher with YHOO), YHOO +1.2% (cont strength), CFMS +0.7% (announces 'positive' results from clinical studies comparing the conformis itotal CR to other total knee replacement products)
Analyst comments: MDRX +5.4% (upgraded to Overweight from Equal-Weight at Morgan Stanley), SHAK +4.6% (upgraded to Buy from Neutral at Longbow), AAPL +1.1% (upgraded to Outperform at Cowen)
In reaction to strong earnings/guidance: LULU +5.3%, ARGS +2.9%, GOL+0.7%
Select metals/mining stocks trading higher: RIO +3.4%, BBL +3.3%, CLF+2.7%, FCX +1.6%, X +1.1%
Select oil/gas related names showing strength: STO +3.7%, CHK +3.5%, BP+3.4%, RDS.A +3.3%, PBR +2.1%, OAS +1.4%
Other news: ACAD +23.7% (affirms favorable AdComm review for NUPLAZID for the treatment of psychosis associated with Parkinson's disease) VICL +16.7% (announces that the FDA has granted fast track designation for its investigational antifungal product candidate, VL-2397, for the treatment of invasive aspergillosis), ATNM +8.9% (granted orphan designation by the FDA for its 131I-BC8 monoclonal antibody for the treatment of Acute Myeloid Leukemia), GLMD +7.5% (pre-clinical data demonstrating significant anti-fibrotic activity of AramcholTM in methionine and choline deficient diet in mice), ADAP +5.1% (confirms orphan drug designation to Adaptimmune's T-cell therapy targeting NY-ESO for treatment of soft tissue sarcoma), VRX +3.9% (launches process to obtain an amendment and waiver to its credit facility, intends to file 10-K on or before April 29), LODE +2.3% (prices offering of 10 mln shares of common stock at $0.35/share), TSLA +1.5% (still checking, likely higher with Futures), BABA +1.4% (trading higher with YHOO), YHOO +1.2% (cont strength), CFMS +0.7% (announces 'positive' results from clinical studies comparing the conformis itotal CR to other total knee replacement products)
Analyst comments: MDRX +5.4% (upgraded to Overweight from Equal-Weight at Morgan Stanley), SHAK +4.6% (upgraded to Buy from Neutral at Longbow), AAPL +1.1% (upgraded to Outperform at Cowen)